Vitamin D test cost in Singapore — and why routine screening isn't what the evidence supports

Last reviewed: August 2026 · Grade: Weak (see full card on Blood Panels)

Vitamin D (25-hydroxyvitamin D, or 25-OH-D) is one of the most heavily marketed add-ons in Singapore health screening packages — sold as a general wellness and immunity check, often bundled with "deficiency panels" alongside iron, B12, and folate. It's also one of the tests where the gap between marketing and evidence is widest on this site: a large randomised trial found supplementing doesn't move the outcomes it's sold on, and the US Preventive Services Task Force has twice — in 2014 and again in 2021 — said there isn't enough evidence to recommend screening asymptomatic adults for it at all.

What the evidence says

Two separate bodies of evidence matter here, and they answer different questions — worth keeping apart:

Does screening asymptomatic adults help? The USPSTF's most recent recommendation statement, "Screening for Vitamin D Deficiency in Adults" (JAMA 2021;325:1436–42, PMID 33847711), concluded the evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in community-dwelling, asymptomatic adults (Grade I) — the Task Force found no studies that directly evaluated whether screening itself changes outcomes. This wasn't a one-off finding: it reaffirmed the same "insufficient evidence" conclusion the USPSTF first reached in 2014 (Ann Intern Med, PMID 25419853). Two independent reviews, seven years apart, same verdict.

Does correcting low levels actually prevent disease? The VITAL trial (Manson JE et al., N Engl J Med 2019;380:33–44, PMID 30415629) randomised 25,871 adults to vitamin D3 2000IU/day or placebo and found no significant reduction in cancer incidence or major cardiovascular events over a 5-year follow-up — the two outcomes vitamin D is most often marketed against in a wellness context. The USPSTF's 2021 review reached a matching conclusion from the treatment side: among asymptomatic people with low levels, correcting vitamin D had no measurable effect on mortality, fractures, falls, depression, diabetes, cardiovascular disease, or cancer.

None of this means vitamin D is unimportant — it means the case for testing and treating is concentrated in specific groups, not the general population. Frank deficiency (commonly defined as <20ng/mL) still matters for bone health, and correcting it is well-supported in people with osteoporosis, malabsorption syndromes, limited sun exposure, dark skin at higher latitudes, obesity, or before starting bone-active therapy (e.g. bisphosphonates). Outside those groups, ordering a 25-OH-D test "just to check" and then supplementing based on a borderline result is exactly the scenario the USPSTF and VITAL trial both found unsupported.

Real Singapore pricing, 2026 — three providers compared

Three Singapore providers checked in August 2026, all quoting a standalone 25-OH-D test:

These three cluster tightly at roughly S$120–135 for a standalone test once GST is accounted for — there isn't a large spread to shop between providers here, unlike some of the other tests on this site. What's notable is the gap against this site's own general evidence card: the Blood Panels page's Vitamin D entry currently lists a general cost estimate of S$50–90, which is meaningfully below what all three providers are actually charging for a standalone 25-OH-D test in 2026. That range likely reflected older pricing or a panel-inclusive assumption rather than a standalone test — see the note in the Gaps section of the project summary; it's being corrected in the same update that ships this article.

Bundled "deficiency screen" panels that include vitamin D alongside iron studies, B12, and folate run higher — ATA Medical's Deficiency Screen (folate, B12, vitamin D, iron studies, ferritin) is S$161.32 NETT, and its Comprehensive/Hair Loss Screen (adds zinc, magnesium, FT4, TSH) is S$263.78 NETT. These bundles can be reasonable value if you genuinely want several of those markers at once, but buying one because vitamin D is included in it is the same "why am I ordering this" problem this site flags for other bundled panels (see article #8 below).

Who should prioritise it

Testing is worthwhile for anyone with osteoporosis or low bone density, malabsorption conditions (e.g. coeliac disease, inflammatory bowel disease, prior bariatric surgery), chronic kidney or liver disease affecting vitamin D metabolism, very limited sun exposure (housebound, fully covered clothing, institutionalised), obesity (which sequesters vitamin D in fat tissue), older age with fall risk, or before starting a bisphosphonate or other bone-active therapy. Outside those groups, the USPSTF's own repeated review found the evidence doesn't support a screening benefit, and the largest treatment trial available found no benefit on the outcomes (cancer, cardiovascular disease) it's most often sold against.

Bottom line

At S$120–135 for a standalone test — clustered tightly across three providers rather than spread wide — the money at stake here is more than some of the other tests on this site, and the evidence case for testing everyone is comparatively weaker: two USPSTF reviews seven years apart both declined to endorse screening, and the largest RCT on supplementation found no benefit on cancer or cardiovascular outcomes. This is Weak-graded not because vitamin D doesn't matter, but because the specific product being sold — a routine 25-OH-D test for an asymptomatic, average-risk adult, often followed by supplementation based on a borderline result — is the exact scenario the evidence doesn't support. Test with a reason; correct confirmed deficiency in the right clinical context; skip it as a default wellness add-on.

Related: full evidence card for Vitamin D on Blood Panels · Thyroid test cost in Singapore · Executive health package pricing · Basic/Intermediate/Advanced testing protocol · how grades are assigned.